Subtype
Bladder Neoplasm
CI-CAN-00001978Explore in graph →
Non-malignant390 active trials10 approved drugs25 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001978Explore in graph →
Clinical trials
1,701 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01611662 | Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer | terminated | Phase 2 | 32 | Fox Chase Cancer CenterOTHER | 1 | Jul 29, 2019 | clinicaltrials |
| NCT02153905 | T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2019 | clinicaltrials |
| NCT01118351 | Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer | terminated | Phase 2 | 19 | Case Comprehensive Cancer CenterOTHER | 1 | May 1, 2019 | clinicaltrials |
| NCT01342172 | Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma | terminated | Phase 1 / Phase 2 | 9 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Apr 23, 2019 | clinicaltrials |
| NCT01435356 | Safety and Efficacy Study of MAGE-A3 + AS-15 in Patients With Muscle-invasive Bladder Cancer After Cystectomy(MAGNOLIA) | terminated | Phase 2 | 83 | European Association of Urology Research FoundationOTHER | 10 | Jan 9, 2019 | clinicaltrials |
| NCT02560038 | Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer | terminated | Phase 2 | 3 | The University of Texas Health Science Center, HoustonOTHER | 1 | Nov 28, 2018 | clinicaltrials |
| NCT02605863 | Enzalutamide for Bladder Cancer Chemoprevention | terminated | Phase 2 | 1 | University of RochesterOTHER | 1 | Oct 3, 2018 | clinicaltrials |
| NCT00089128 | Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer | terminated | Phase 2 | 16 | Medical University of South CarolinaOTHER | 1 | Jul 12, 2018 | clinicaltrials |
| NCT00268450 | Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery | terminated | Phase 2 | 21 | Medical University of South CarolinaOTHER | 1 | Jul 12, 2018 | clinicaltrials |
| NCT01331824 | Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma | terminated | Phase 2 | 22 | Matthew GalskyOTHER | 1 | Apr 23, 2018 | clinicaltrials |
| NCT00003452 | Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Bladder | terminated | Phase 2 | 4 | Burzynski Research InstituteOTHER | 1 | Sep 28, 2017 | clinicaltrials |
| NCT01622660 | Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy | terminated | Phase 2 | 2 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 22, 2017 | clinicaltrials |
| NCT01042795 | Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy | terminated | Phase 2 | 7 | University of MichiganOTHER | 1 | Jun 28, 2017 | clinicaltrials |
| NCT01475266 | Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) | terminated | Phase 2 / Phase 3 | 51 | Nippon Kayaku Co., Ltd.INDUSTRY | 2 | Mar 29, 2017 | clinicaltrials |
| NCT02030574 | Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin | terminated | Phase 2 | 2 | Brown UniversityOTHER | 1 | Aug 24, 2016 | clinicaltrials |
| NCT00022633 | S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract | terminated | Phase 2 | 65 | SWOG Cancer Research NetworkNETWORK | 1 | Aug 11, 2016 | clinicaltrials |
| NCT01339000 | Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Jun 22, 2016 | clinicaltrials |
| NCT01916109 | Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer | terminated | Phase 2 | 4 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 12, 2016 | clinicaltrials |
| NCT01663285 | Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC) | terminated | Phase 2 | 1 | University of Michigan Rogel Cancer CenterOTHER | 1 | Dec 3, 2015 | clinicaltrials |
| NCT00714948 | Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma | terminated | Phase 2 | 2 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 16, 2015 | clinicaltrials |
| NCT00479089 | Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer | terminated | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 2, 2015 | clinicaltrials |
| NCT00635726 | Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer | terminated | Phase 2 | 41 | Hellenic Oncology Research GroupOTHER | 1 | Oct 8, 2015 | clinicaltrials |
| NCT00995488 | Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer | terminated | Phase 2 | 16 | University of Michigan Rogel Cancer CenterOTHER | 1 | Sep 11, 2015 | clinicaltrials |
| NCT01374789 | PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer(PURO) | terminated | Phase 2 | 2 | WiSP Wissenschaftlicher Service Pharma GmbHOTHER | 1 | Jun 3, 2015 | clinicaltrials |
| NCT00933374 | Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma(RAD001) | terminated | Phase 2 | 28 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Mar 18, 2015 | clinicaltrials |
| NCT00393796 | Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma | terminated | Phase 2 | 54 | University of Michigan Rogel Cancer CenterOTHER | 1 | Nov 13, 2014 | clinicaltrials |
| NCT00112905 | Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium | terminated | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00516750 | Gene Expression Profiling in Patients With Invasive Bladder Cancer Receiving Methotrexate, Vinblastine, Doxorubicin, and Cisplatin | terminated | Phase 2 | 100 | Kyoto UniversityOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00004856 | Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium | terminated | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | May 3, 2013 | clinicaltrials |
| NCT00087295 | S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium | terminated | Phase 2 | 6 | SWOG Cancer Research NetworkNETWORK | 0 | Nov 2, 2012 | clinicaltrials |
| NCT01551407 | Detection of Bladder Tumors After 30 Min Instillation of Hexvix | terminated | Phase 2 | 38 | PhotocureINDUSTRY | 1 | Oct 25, 2012 | clinicaltrials |
| NCT00003640 | Transurethral Resection and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer | terminated | Phase 2 | 73 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Mar 6, 2012 | clinicaltrials |
| NCT00003642 | Radiation Therapy and Chemotherapy Following Surgery in Treating Patients With Stage II or Stage III Bladder Cancer | terminated | Phase 2 | 43 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 2 | Mar 6, 2012 | clinicaltrials |
| NCT01215266 | Sorafenib in Urothelium Cancer of Bladder | terminated | Phase 2 | 98 | Association of Urologic Oncology (AUO)OTHER | 0 | Sep 8, 2011 | clinicaltrials |
| NCT00050687 | Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies | terminated | Phase 1 / Phase 2 | — | Titan PharmaceuticalsINDUSTRY | 1 | Jan 28, 2011 | clinicaltrials |
Data updated 22 days agoSource updated Jul 29, 2019source: clinicaltrials